Allocating the Sample Size in Phase II and III Trials to Optimize Success Probability
<p>{\bf Background} Clinical trials of phase II and III often fail due to poor experimental planning. Here, the problem of allocating available resources, in terms of sample size, to phase II and phase III is studied with the aim of increasing success rate. The overall success probability (OSP...
Saved in:
| Main Author: | Daniele De Martini |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Milano University Press
2014-11-01
|
| Series: | Epidemiology, Biostatistics and Public Health |
| Online Access: | http://ebph.it/article/view/9958 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phase III Failures for a Lack of Efficacy can be, in Significant Part, Recovered (Introducing Success Probability Estimation Quantitatively)
by: Daniele De Martini
Published: (2023-07-01) -
drugdevelopR: Planning of phase II/III drug development programs with optimal sample size allocation and Go/No-go decision rules in R
by: Johannes Cepicka, et al.
Published: (2025-05-01) -
Distributions of Wide Binary Stars in Theory and in Gaia Data. II. Reconstruction of Sample Probability Density of True Orbit Sizes
by: Valeri V. Makarov
Published: (2025-01-01) -
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
by: Miranta Antoniou, et al.
Published: (2016-01-01) -
Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics
by: Josephine Bourner, et al.
Published: (2025-02-01)